Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 117,504,880
  • Shares Outstanding, K 253,719
  • Annual Sales, $ 11,020 M
  • Annual Income, $ -535,600 K
  • EBIT $ 3,993 M
  • EBITDA $ 4,201 M
  • 60-Month Beta 0.32
  • Price/Sales 9.97
  • Price/Cash Flow N/A
  • Price/Book 6.41

Options Overview Details

View History
  • Implied Volatility 22.94% (-0.22%)
  • Historical Volatility 27.55%
  • IV Percentile 2%
  • IV Rank 2.80%
  • IV High 52.99% on 12/18/24
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 8) 11.48 (2.51%)
  • Put/Call Vol Ratio 1.41
  • Today's Volume 2,834
  • Volume Avg (30-Day) 2,717
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 41,545
  • Open Int (30-Day) 43,371
  • Expected Range 445.89 to 468.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 33 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 4.34
  • Number of Estimates 10
  • High Estimate 4.77
  • Low Estimate 3.99
  • Prior Year 3.54
  • Growth Rate Est. (year over year) +22.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
406.67 +12.46%
on 11/07/25
463.85 -1.40%
on 12/03/25
+35.69 (+8.46%)
since 11/04/25
3-Month
374.17 +22.23%
on 09/24/25
463.85 -1.40%
on 12/03/25
+60.43 (+15.22%)
since 09/04/25
52-Week
362.50 +26.17%
on 08/11/25
519.68 -11.99%
on 03/14/25
-6.62 (-1.43%)
since 12/04/24

Most Recent Stories

More News
Stocks Climb on Fed Rate Cut Optimism

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up by +0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.86%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.20%. December...

MSTR : 186.01 (-1.26%)
AMAT : 269.44 (+0.30%)
GTLB : 37.51 (-0.85%)
ACHC : 14.64 (-0.34%)
DHI : 160.73 (-2.59%)
ADI : 277.26 (-0.35%)
FISV : 66.06 (-1.33%)
GLXY : 27.57 (+1.92%)
BLDR : 111.01 (-3.00%)
TXN : 180.12 (-1.36%)
$IUXX : 25,581.70 (-0.10%)
COIN : 274.05 (-1.04%)
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today

Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today

VRTX : 457.36 (-1.25%)
Stocks Recover on Fed Rate Cut Expectations

The S&P 500 Index ($SPX ) (SPY ) today is up by +0.18%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.06%. December E-mini S&P...

MSTR : 186.01 (-1.26%)
GTLB : 37.51 (-0.85%)
ACHC : 14.64 (-0.34%)
DHI : 160.73 (-2.59%)
FISV : 66.06 (-1.33%)
GLXY : 27.57 (+1.92%)
BLDR : 111.01 (-3.00%)
TXN : 180.12 (-1.36%)
$IUXX : 25,581.70 (-0.10%)
COIN : 274.05 (-1.04%)
ASML : 1,110.08 (-2.70%)
ZNH26 : 112-260 (+0.08%)
Stocks Pressured by Labor Market Weakness and AI-Demand Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.49%. December E-mini S&P...

MSTR : 186.01 (-1.26%)
GTLB : 37.51 (-0.85%)
ACHC : 14.64 (-0.34%)
DHI : 160.73 (-2.59%)
GLXY : 27.57 (+1.92%)
BLDR : 111.01 (-3.00%)
TXN : 180.12 (-1.36%)
$IUXX : 25,581.70 (-0.10%)
M : 22.32 (-0.62%)
COIN : 274.05 (-1.04%)
ZNH26 : 112-260 (+0.08%)
PHVS : 27.69 (-5.70%)
Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq?

Vertex Pharmaceuticals has underperformed the broader Nasdaq index over the past year. However, Wall Street analysts remain moderately optimistic about its prospects.

$NASX : 23,505.14 (+0.22%)
VRTX : 457.36 (-1.25%)
ALNY : 465.34 (-1.68%)
Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why

Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why

VRTX : 457.36 (-1.25%)
Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi’s 2025 Global Healthcare Conference. Charlie Wagner, Chief Operating and Financial Officer,...

VRTX : 457.36 (-1.25%)
This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?

CRISPR Therapeutics is the subject of strong buyout speculation after earning FDA approval for a breakthrough gene-editing therapy.

CRSP : 58.18 (+3.91%)
VRTX : 457.36 (-1.25%)
1 Cash-Heavy Stock with Solid Fundamentals and 2 We Ignore

1 Cash-Heavy Stock with Solid Fundamentals and 2 We Ignore

FSUN : 35.08 (+1.24%)
VRTX : 457.36 (-1.25%)
CRM : 247.46 (+3.66%)
Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings

Vertex Pharmaceuticals’ stock has trailed behind the broader market, but analysts are still taking a moderately bullish stance about its prospects.

XLV : 153.90 (-0.76%)
$SPX : 6,857.12 (+0.11%)
VRTX : 457.36 (-1.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 473.02
2nd Resistance Point 468.36
1st Resistance Point 462.86
Last Price 457.36
1st Support Level 452.70
2nd Support Level 448.04
3rd Support Level 442.54

See More

52-Week High 519.68
Fibonacci 61.8% 459.64
Last Price 457.36
Fibonacci 50% 441.09
Fibonacci 38.2% 422.54
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar